These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33301525)

  • 1. Reduction of free polysaccharide contamination in the production of a 15-valent pneumococcal conjugate vaccine.
    Whang YH; Kim SK; Yoon H; Choi SK; Baik YO; Lee C; Lee I
    PLoS One; 2020; 15(12):e0243909. PubMed ID: 33301525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expanding the Scope of Ugi Multicomponent Bioconjugation to Produce Pneumococcal Multivalent Glycoconjugates as Vaccine Candidates.
    Humpierre AR; Zanuy A; Saenz M; Garrido R; Vasco AV; Pérez-Nicado R; Soroa-Milán Y; Santana-Mederos D; Westermann B; Vérez-Bencomo V; Méndez Y; García-Rivera D; Rivera DG
    Bioconjug Chem; 2020 Sep; 31(9):2231-2240. PubMed ID: 32809806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current trends in development and manufacturing of higher-valent pneumococcal polysaccharide conjugate vaccine and its challenges.
    Jain SS; Singh VK; Kante RK; Jana SK; Patil RH
    Biologicals; 2024 Aug; 87():101784. PubMed ID: 39053122
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A dose ranging study of 2 different formulations of 15-valent pneumococcal conjugate vaccine (PCV15) in healthy infants.
    Rupp R; Hurley D; Grayson S; Li J; Nolan K; McFetridge RD; Hartzel J; Abeygunawardana C; Winters M; Pujar H; Benner P; Musey L
    Hum Vaccin Immunother; 2019; 15(3):549-559. PubMed ID: 30689507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Streptococcus pneumoniae Type 2 Oligosaccharide Glycoconjugate Elicits Opsonic Antibodies and Is Protective in an Animal Model of Invasive Pneumococcal Disease.
    Emmadi M; Khan N; Lykke L; Reppe K; G Parameswarappa S; Lisboa MP; Wienhold SM; Witzenrath M; Pereira CL; Seeberger PH
    J Am Chem Soc; 2017 Oct; 139(41):14783-14791. PubMed ID: 28945368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-clinical immunological comparison of a Next-Generation 24-valent pneumococcal conjugate vaccine (VAX-24) using site-specific carrier protein conjugation to the current standard of care (PCV13 and PPV23).
    Fairman J; Agarwal P; Barbanel S; Behrens C; Berges A; Burky J; Davey P; Fernsten P; Grainger C; Guo S; Iki S; Iverson M; Kane M; Kapoor N; Marcq O; Migone TS; Sauer P; Wassil J
    Vaccine; 2021 May; 39(23):3197-3206. PubMed ID: 33965258
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Experience with pneumococcal polysaccharide conjugate vaccine (conjugated to CRM197 carrier protein) in children and adults.
    Durando P; Faust SN; Fletcher M; Krizova P; Torres A; Welte T
    Clin Microbiol Infect; 2013 Oct; 19 Suppl 1():1-9. PubMed ID: 24083785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine.
    Peterson JT; Stacey HL; MacNair JE; Li J; Hartzel JS; Sterling TM; Benner P; Tamms GM; Musey LK
    Hum Vaccin Immunother; 2019; 15(3):540-548. PubMed ID: 30427749
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine in pneumococcal vaccine-naïve adults ≥50 years of age.
    Ermlich SJ; Andrews CP; Folkerth S; Rupp R; Greenberg D; McFetridge RD; Hartzel J; Marchese RD; Stek JE; Abeygunawardana C; Musey LK
    Vaccine; 2018 Oct; 36(45):6875-6882. PubMed ID: 29559167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human monoclonal antibodies isolated from a primary pneumococcal conjugate Vaccinee demonstrates the expansion of an antigen-driven Hypermutated memory B cell response.
    Chen Z; Cox KS; Tang A; Roman J; Fink M; Kaufhold RM; Guan L; Xie A; Boddicker MA; Mcguinness D; Xiao X; Li H; Skinner JM; Verch T; Retzlaff M; Vora KA
    BMC Infect Dis; 2018 Dec; 18(1):613. PubMed ID: 30509199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of pneumococcal polysaccharide vaccines: no simple answers.
    French N
    J Infect; 2003 Feb; 46(2):78-86. PubMed ID: 12634068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoconjugate vaccines: some observations on carrier and production methods.
    MacCalman TE; Phillips-Jones MK; Harding SE
    Biotechnol Genet Eng Rev; 2019 Oct; 35(2):93-125. PubMed ID: 32048549
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a new 15-valent pneumococcal conjugate vaccine (PCV15) and evaluation of its immunogenicity.
    Lee C; Choi SK; Kim RK; Kim H; Whang YH; Pharm H; Cheon H; Yoon DY; Kim CW; Baik YO; Park SS; Lee I
    Biologicals; 2019 Sep; 61():32-37. PubMed ID: 31416790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity Comparison of a Next Generation Pneumococcal Conjugate Vaccine in Animal Models and Human Infants.
    Xie J; Zhang Y; Caro-Aguilar I; Indrawati L; Smith WJ; Giovarelli C; Winters MA; MacNair J; He J; Abeygunawardana C; Musey L; Kosinski M; Skinner JM
    Pediatr Infect Dis J; 2020 Jan; 39(1):70-77. PubMed ID: 31725555
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pre-clinical evaluation of a 15-valent pneumococcal conjugate vaccine (PCV15-CRM197) in an infant-rhesus monkey immunogenicity model.
    Skinner JM; Indrawati L; Cannon J; Blue J; Winters M; Macnair J; Pujar N; Manger W; Zhang Y; Antonello J; Shiver J; Caulfield M; Heinrichs JH
    Vaccine; 2011 Nov; 29(48):8870-6. PubMed ID: 21964055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pneumococcal conjugate vaccines. A review.
    Galiza EP; Heath PT
    Minerva Med; 2007 Apr; 98(2):131-43. PubMed ID: 17519855
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing potential benefits of new pneumococcal vaccines with the current polysaccharide vaccine in the elderly.
    Fry AM; Zell ER; Schuchat A; Butler JC; Whitney CG
    Vaccine; 2002 Dec; 21(3-4):303-11. PubMed ID: 12450706
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adults.
    Jackson LA; Gurtman A; van Cleeff M; Jansen KU; Jayawardene D; Devlin C; Scott DA; Emini EA; Gruber WC; Schmoele-Thoma B
    Vaccine; 2013 Aug; 31(35):3577-84. PubMed ID: 23688526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.